This inventor holds 1 USPTO granted patent. Top assignees: King Abdulaziz University, University of Jeddah. Active years: 2025.
Company Filing History:
1 out of 588 
1 out of 12 Years Active: 2025
Title: Innovations in Cancer Treatment by Mohammad Basabrain
Introduction
Mohammad Basabrain is an accomplished inventor based in Jeddah, Saudi Arabia. He has made significant contributions to the field of cancer research, particularly in the treatment of acute myeloid leukemia (AML). His innovative approach has led to the development of a promising therapeutic agent that targets AML cells.
Latest Patents
Mohammad Basabrain holds a patent for a compound titled "2-(5-aminopyridin-2-yl)-N-benzylacetamides and use thereof in the treatment of acute myeloid leukemia." This patent identifies three compounds with a common molecular template, which are recognized as potential anticancer therapeutic agents. Compound I, in particular, was designed to specifically target AML cells, inhibit their growth, and induce cell death. It has demonstrated a dose-dependent effect on various AML cell lines, including HL-60, Mv4-11, KG-1a, and K562.
Career Highlights
Throughout his career, Mohammad Basabrain has worked with prestigious institutions such as the University of Jeddah and King Abdulaziz University. His research has focused on developing effective treatments for cancer, showcasing his dedication to improving patient outcomes.
Collaborations
Mohammad has collaborated with notable colleagues, including Roaa M Alreemi and Hind A Alkhatabi. Their combined efforts have contributed to the advancement of cancer research and the development of innovative therapeutic solutions.
Conclusion
In summary, Mohammad Basabrain is a pioneering inventor whose work in cancer treatment has the potential to make a significant impact on the lives of patients suffering from acute myeloid leukemia. His innovative compounds represent a promising step forward in the fight against cancer.